SYMBICORT 160/4.5 for the maintenance treatment of COPD, and for reducing COPD exacerbations
SYMBICORT for asthma patients ≥12 years of age uncontrolled on an ICS or whose disease warrants initiation of treatment with both an ICS and a LABA
Sustained improvement in lung function was demonstrated in asthma patients ≥12 years of age in two 12-week efficacy and safety studies.1
Majority of patients’ FEV1† improvement occurred at 5 minutes in COPD and 15 minutes in asthma1,3-6
Sustained improvement in lung function was demonstrated in a 12-month efficacy and safety study in COPD and a 12-week efficacy
and safety study in asthma.3-6
SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
See study designs and data by clicking the links above.
*Based on IQVIA NPA Total Rx volume data among ICS/LABA, long-acting muscarinic antagonist (LAMA)/LABA, ICS, LAMA, ICS/LAMA/LABA, and
LABA markets from July 2019 to June 2020.2